Multiple Primary Lung Cancers Clinical Trial
Official title:
The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density: A Prospective Interventional Two-stage Simon Design Phase II Study.
A single-center,prospective interventional study to explore the efficacy of PD-1 antibody Sintilimab on early-stage multiple primary lung cancer patients with ground-glass nodules in CT scan.
This study is a single-center,prospective interventional clinical study, all subjects enrolled are multiple primary lung cancer patients with ground-glass density in CT scan.The samples plan for the study was 36 cases.The enrolled patients will receive intravenous infusion of Sintilimab 200mg every 3 weeks up to 4 cycles, and the efficacy will be evaluated after cycle 2 and 4 using RECIST criteria (version 1.1 ). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04982900 -
Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities
|
Phase 2 | |
| Not yet recruiting |
NCT04326751 -
Evolution of Multiple Primary Lung Cancer (Evolution)
|